Bicara Therapeutics Inc. Common Stock (BCAX) quarterly income statement — complete revenue, gross profit & net income history
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Revenue Growth % | - | - | - | - | - | - | - | - | - | - | - |
| Cost of Goods Sold | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| COGS % of Revenue | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit Growth % | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | 60.24M | 41.12M | 40.68M | 32.02M | 41.79M | 26.64M | 20.63M | 19.75M | 15.37M | 13.69M | 8.34M |
| OpEx % of Revenue | - | - | - | - | - | - | - | - | - | - | - |
| Selling, General & Admin | 12.74M | 8.13M | 7.7M | 7.22M | 7.46M | 6.75M | 4.76M | 3.91M | 3.34M | 3.13M | 1.78M |
| SG&A % of Revenue | - | - | - | - | - | - | - | - | - | - | - |
| Research & Development | 47.5M | 32.99M | 5.82M | 24.8M | 34.33M | 19.88M | 15.86M | 15.84M | 12.03M | 10.56M | 6.56M |
| R&D % of Revenue | - | - | - | - | - | - | - | - | - | - | - |
| Other Operating Expenses | 0 | 0 | 1000K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -60.24M | -41.12M | -40.68M | -32.02M | -41.79M | -26.64M | -20.63M | -19.75M | -15.37M | -13.69M | -8.34M |
| Operating Margin % | - | - | - | - | - | - | - | - | - | - | - |
| Operating Income Growth % | -44.16% | -54.38% | -97.19% | -62.12% | -171.81% | -94.62% | - | - | -84.43% | - | - |
| EBITDA | -60.24M | -41.11M | -40.62M | -32M | -41.77M | -26.62M | -20.61M | -19.74M | -15.36M | -13.67M | -8.33M |
| EBITDA Margin % | - | - | - | - | - | - | - | - | - | - | - |
| EBITDA Growth % | -44.23% | -54.42% | -97.06% | -62.13% | -171.92% | -94.7% | - | - | -84.31% | - | - |
| D&A (Non-Cash Add-back) | 0 | 11K | 56K | 19K | 19K | 15K | 15K | 13K | 13K | 14K | 1.5K |
| EBIT | -60.24M | -41.12M | -36.29M | -32.02M | -41.79M | -26.64M | -20.63M | -19.75M | -15.37M | -25.78M | -8.34M |
| Net Interest Income | 4.08M | 3.79M | 4.39M | 4.68M | 5.01M | 5.87M | 3.15M | 2.7M | 2.87M | 1.3M | 0 |
| Interest Income | 4.08M | 3.79M | 4.39M | 4.68M | 5.01M | 5.87M | 3.15M | 2.7M | 2.87M | 1.3M | 0 |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Income/Expense | 4.08M | 3.79M | 4.39M | 4.68M | 5.01M | 5.87M | 3.15M | 2.7M | 2.87M | 1.25M | -14K |
| Pretax Income | -56.16M | -37.33M | -36.29M | -27.34M | -36.77M | -20.77M | -17.48M | -17.05M | -12.51M | -12.44M | -8.35M |
| Pretax Margin % | - | - | - | - | - | - | - | - | - | - | - |
| Income Tax | -52K | 53K | 40K | 52K | 72K | 186K | 0 | 0 | 1K | 5K | 0 |
| Effective Tax Rate % | 0.09% | -0.14% | -0.11% | -0.19% | -0.2% | -0.9% | 0% | 0% | -0.01% | -0.04% | 0% |
| Net Income | -56.21M | -37.39M | -36.33M | -27.39M | -36.85M | -20.96M | -17.48M | -17.05M | -12.51M | -12.44M | -8.35M |
| Net Margin % | - | - | - | - | - | - | - | - | - | - | - |
| Net Income Growth % | -52.56% | -78.39% | -107.83% | -60.64% | -194.58% | -68.46% | - | - | -49.8% | - | - |
| Net Income (Continuing) | -56.11M | -37.39M | -36.33M | -27.39M | -36.85M | -20.96M | -17.48M | -17.05M | -12.51M | -12.44M | -8.35M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.93 | -0.68 | -0.67 | -0.50 | -0.68 | -0.38 | -0.32 | -0.27 | -0.27 | -0.23 | -0.15 |
| EPS Growth % | -36.76% | -78.95% | -109.38% | -85.19% | -151.85% | -65.22% | - | - | -80% | - | - |
| EPS (Basic) | -0.93 | -0.68 | -0.67 | -0.50 | -0.68 | -0.38 | -0.32 | -0.27 | -0.27 | -0.23 | -0.15 |
| Diluted Shares Outstanding | 60.72M | 55.14M | 54.56M | 54.54M | 54.46M | 54.44M | 54.41M | 54.18M | 54.18M | 53.09M | 54.62M |
| Basic Shares Outstanding | 60.72M | 55.14M | 54.56M | 54.54M | 54.46M | 54.44M | 54.41M | 54.18M | 54.18M | 53.09M | 54.6M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - | - |